Evaluation of the Relationship between Serum Ghrelin, C-Reactive Protein and Interleukin-6 Levels, and Disease Activity in Inflammatory Bowel Diseases

被引:18
作者
Cekic, Cem [1 ]
Arabul, Mahmut [1 ]
Alper, Emrah [1 ]
Pakoz, Zehra Betul Kocal [1 ]
Saritas, Elif [1 ]
Yuksel [1 ]
Unsal, Belkis [1 ]
机构
[1] Ataturk Training & Res Hosp, Dept Gastroenterol, Izmir, Turkey
关键词
Inflammatory bowel disease; Ghrelin; Disease activity; NECROSIS-FACTOR-ALPHA; CROHNS-DISEASE; LEPTIN; EXPRESSION; THERAPY; MARKERS;
D O I
10.5754/hge11991
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background/Aims: Ghrelin is a 28 aminoasid peptide hormone, have generally focused upon this peptide's role upon growth and energy metabolism. Recently, studies investigating ghrelin's effect upon inflammation and immune response have gained importance. We aimed to compare the effectiveness of ghrelin levels, Creactive protein and interleukin-6 levels in establishing disease activity. Methodology: 52 cases with ulcerative colitis and 33 with Crohn's disease, total 85 patients, were included in this study. The serum ghrelin levels of the patients in remission and of those with active disease were compared. Results: The mean serum ghrelin level in active patients (1243 +/- 648 pg/ml), to be higher than those in remission (466 +/- 214 pg/ml) (p<0.001). In establishing the disease activity, CRP is a the most effective marker compared to the other two inflammatory markers. AUC values were established as; CRP: 0.947 (95% CI,0.903-0.992),ghrelin:0.934(95% CI 0.884-0.984) and interleukin-6: 0.756 (95% CI, 0.648-0.864). Discussion: Serum ghrelin level can be used with CRP as an important marker in establishing the mucosal damage in inflammatory bowel diseases.
引用
收藏
页码:1196 / 1200
页数:5
相关论文
共 33 条
[1]
Obestatin/Ghrelin Ratio: A New Activity Index in Inflammatory Bowel Diseases [J].
Alexandridis, Efstratios ;
Zisimopoulos, Athanasios ;
Liratzopoulos, Nikolaos ;
Katsos, Ioannis ;
Manolas, Konstantinos ;
Kouklakis, Georgios .
INFLAMMATORY BOWEL DISEASES, 2009, 15 (10) :1557-1561
[2]
ASSESSMENT OF APPROPRIATE LABORATORY MEASUREMENTS TO SUPPLEMENT THE CROHNS-DISEASE ACTIVITY INDEX [J].
ANDRE, C ;
DESCOS, L ;
LANDAIS, P ;
FERMANIAN, J .
GUT, 1981, 22 (07) :571-574
[3]
Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status [J].
Ates, Yuksel ;
Degertekin, Bulent ;
Erdil, Ahmet ;
Yaman, Halil ;
Dagalp, Kemal .
DIGESTIVE DISEASES AND SCIENCES, 2008, 53 (08) :2215-2221
[4]
Ghrelin: The link connecting growth with metabolism and energy homeostasis [J].
Casanueva F.F. ;
Dieguez C. .
Reviews in Endocrine and Metabolic Disorders, 2002, 3 (4) :325-338
[5]
Endogenous and exogenous ghrelin enhance the colonic and gastric manifestations of dextran sodium sulphate-induced colitis in mice [J].
De Smet, B. ;
Thijs, T. ;
Moechars, D. ;
Colsoul, B. ;
Polders, L. ;
Donck, L. Ver ;
Coulie, B. ;
Peeters, T. L. ;
Depoortere, I. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2009, 21 (01) :59-70
[6]
Review article: biological activity markers in inflammatory bowel disease [J].
Desai, D. ;
Faubion, W. A. ;
Sandborn, W. J. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (03) :247-255
[7]
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management [J].
Dignass, A. ;
Van Assche, G. ;
Lindsay, J. O. ;
Lemann, M. ;
Soderholm, J. ;
Colombel, J. F. ;
Danese, S. ;
D'Hoore, A. ;
Gassull, M. ;
Gomollon, F. ;
Hommes, D. W. ;
Michetti, P. ;
O'Morain, C. ;
Oresland, T. ;
Windsor, A. ;
Stange, E. F. ;
Travis, S. P. L. .
JOURNAL OF CROHNS & COLITIS, 2010, 4 (01) :28-62
[8]
Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells [J].
Dixit, VD ;
Schaffer, EM ;
Pyle, RS ;
Collins, GD ;
Sakthivel, SK ;
Palaniappan, R ;
Lillard, JW ;
Taub, DD .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (01) :57-66
[9]
Clinically active Crohn's disease in the presence of a low C-reactive protein [J].
Florin, THJ ;
Paterson, EWJ ;
Fowler, EV ;
Radford-Smith, GL .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2006, 41 (03) :306-311
[10]
Anti-tumour necrosis factor α therapy modulates ghrelin in patients with severe rheumatoid arthritis [J].
Gonzalez-Gay, M. A. ;
Garcia-Unzueta, M. T. ;
Berja, A. ;
Vazquez-Rodriguez, T. R. ;
Gonzalez-Juanatey, C. ;
de Matias, J. M. ;
Martin, J. ;
Dessein, P. H. ;
Llorca, J. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1644-1646